☆ 4.6 Editorial Material

Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma

LIVER CANCER (2022)

Get Full Text
Add to Collection

Journal

LIVER CANCER
Volume 11, Issue 5, Pages 399-406

Publisher

KARGER
DOI: 10.1159/000526163

Keywords

Atezolizumab plus bevacizumab; Hepatocellular carcinoma; ABC conversion; Curative therapy; Cancer-free status; Drug-free status

Categories

Oncology Gastroenterology & Hepatology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.